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Abstract: Cancer stem cells are defined as a subpopulation of cells within a tumor that are 
capable of self-renewal and differentiation into the heterogeneous cell lineages that 
comprise the tumor. Many studies indicate that cancer stem cells may be responsible for 
treatment failure and relapse in cancer patients. The factors that regulate cancer stem cells 
are not well defined. MicroRNAs (miRNAs) are small non-coding RNAs that regulate 
translational repression and transcript degradation. miRNAs play a critical role in 
embryonic and inducible pluripotent stem cell regulation and emerging evidence supports 
their role in cancer stem cell evolution. To date, miRNAs have been shown to act either as 
tumor suppressor genes or oncogenes in driving critical gene expression pathways in 
cancer stem cells in a wide range of human malignancies, including hematopoietic and 
epithelial tumors and sarcomas. miRNAs involved in cancer stem cell regulation provide 
attractive, novel therapeutic targets for cancer treatment. This review attempts to 
summarize progress to date in defining the role of miRNAs in cancer stem cells. 
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1. Introduction 
MicroRNAs (miRNAs) are a group of small (~18–25 nucleotide) non-protein encoding RNAs that 
have recently been established as important regulators of gene expression, through which they play 
critical roles in cellular processes such as differentiation, proliferation and apoptosis. Numerous 
studies have demonstrated that the effects of miRNAs on gene expression have significant implications 
for development and oncogenesis. With their discovery in 1993 in C. elegans models [1,2], a new 
paradigm of gene regulation was born: miRNAs silence gene targets by binding to complementary 
regions in the 3' untranslated region (UTR) of messenger RNAs (mRNA), leading to degradation of 
mRNA or inhibition of translation, ultimately causing a decrease in protein expression [3]. 
miRNAs appear to play an important role in the development and progression of cancers, a role that 
is mediated by alterations in the miRNA expression level or ability to bind its target. Aberrant miRNA 
expression or binding occurs through diverse mechanisms, including genomic amplification or 
deletion, epigenetic silencing, or point mutations occurring in the miRNA or target sequences [3], 
indicating that miRNAs can serve as either oncogenes (in which context they are referred to as 
“oncomirs”) or tumor suppressor genes. miRNAs have been implicated in tumor initiation [4], 
progression, metastasis [5] and, importantly, in the formation and maintenance of cancer stem cells [6]. 
Cancer stem cells (CSC) are defined as a group of cells within the tumor that have the capacity to 
self-renew and differentiate into multiple cell types [7,8]. As such, they have the potential to 
regenerate tumors after therapy and seed distant metastases; thus CSCs appear critical to development 
of treatment failure [9]. These observations are now driving a significant effort to identify therapeutic 
targets within the cancer stem cell population. 
miRNAs have a demonstrated role in embryonic stem cell maintenance; similar features define 
embryonic and cancer stem cells. Particularly compelling evidence for a link between embryonic stem 
cells and cancer came with genome-wide expression analyses that revealed similar profiles in 
embryonic stem cells and aggressive forms of human cancer [10]. Given our increasing understanding 
of miRNAs as genome-wide regulators [11], manipulation of miRNAs holds potential as a means of 
attacking the cancer stem cell population [12]. 
Over 1,000 miRNA sequences have been recognized in the human genome [13]. In addition to 
holding promise as therapeutic targets, miRNAs are promising as biomarkers for diagnosis and 
prognosis. For instance, high levels of miR205a expression distinguishes primary lung squamous cell 
carcinoma from adenocarcinoma [14,15]. miR21 overexpression has been found to be a poor 
prognostic indicator in multiple tumor types including breast cancer [16] and pancreatic cancer, in 
which it predicts chemotherapy resistance [17,18] and tumor aggressiveness [19]. In contrast, reduced 
expression of miR146a is associated with increased pancreatic cancer invasion, with re-expression of 
miR146a leading to downregulation of IRAK11 mediated signaling through EGFR and NF-kappa B 
and reduction of cancer cell invasiveness [20]. In vitro studies demonstrated that application of a 
naturally occurring isoflavone to pancreatic cancer cells could increase miR146a levels and thus 
reduce invasiveness, thus providing a novel therapeutic target in this uniformly deadly disease [20]. 
One of the challenges facing the field of cancer stem cell biology is defining the characteristics of 
this population in any individual tumor. The first models of CSC were demonstrated using leukemia 
cells, in which CD34+/CD38- cell fractions alone were able to recapitulate disease morphology when Cancers 2011, 3                                       
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transplanted into immunocompromised mice [21,22] In solid tumors, small populations of cancer stem 
cells have been defined by expression of cell-surface markers such as CD133 (in colon cancer) or 
CD44 (in breast cancer) and the ability to form tumors in immune-deficient mice [9,23-25]. Aldehyde 
dehydrogenase (ALDH) is highly active in stem cells in multiple tissue types [26-28], is detectable 
using enzymatic assays or by immunohistochemistry and may serve as a useful intracellular marker of 
this population [29]. The interplay between markers of cancer stem cell populations and miRNAs may 
have significant implications for targeting the stem cell niche for therapeutic purposes. 
2. The Role of miRNAs in Embryonic Stem Cells and Induced Pluripotent Stem Cells 
Drivers of pluripotency include the transcription factors Oct4, Nanog, Sox2, and cMyc, among 
others. The reprogramming of human embryonic fibroblasts and newborn and adult fibroblasts through 
the ectopic expression of human Oct4, Sox2, Klf4 and c-Myc generates human inducible pluripotent 
stem (iPS) cells [30,31]. These factors appear to engage in cross-talk with miRNAs, leading to 
coordinated regulation in embryonic stem cells; studies in these cells suggest that miRNAs are part of 
a core regulatory program that permits pluripotency, self-renewal, and differentiation [32]. A number 
of miRNAs have been identified as key regulators of pluripotency and/or self-renewal and 
proliferation; a few of these are discussed below and highlighted in Figure 1. 
Figure 1. An overview of major gene and miRNA regulators of pluripotency and 
differentiation. LIN28 and let7 interact directly; LIN28 dominance tips the balance in favor 
of self-renewal whereas let7 dominance drives differentiation programs. Members of the 
miR17-92 cluster are turned on by cMyc and keep its pro-proliferative signals through 
E2F1 in check. Oct4 upregulates miR302; together they block differentiation signals via 
NR2F2; miR302 also puts the brake on the cell cycle, so cells in which it is highly 
expressed are relatively quiescent. 
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Evidence for the association between miRNAs and “stemness” mounted in studies showing that 
expression of OCT4, SOX2, NANOG, and LIN28 could reprogram adult human fibroblasts to 
inducible pluripotent stem cells [33], suggesting that the miRNA LIN28 and its regulatory target, let-7, 
play a critical role in maintenance of stem cells. Subsequent work demonstrated that the LIN28/let7 
pair appears to act as a “toggle switch” between pluripotency and differentiation in embryonic stem 
cells [34]. The let7 family of miRNAs are maintained in their precursor forms by the binding of LIN28 
to their terminal loops, thus blocking their processing to the mature state [35]. As a result, in 
conditions of high LIN28 expression, such as in stem cells, let-7 miRNAs are absent or expressed only 
at low levels [36]. Conversely, LIN28 is down-regulated during differentiation, relieving the inhibition 
on let7 [37]. Let7 miRNAs have been demonstrated to repress a broad range of targets, including 
Lin28, cMyc, nMyc, Sall4, and downstream effectors of the pluripotency genes NANOG, OCT4 and 
SOX2 [38]. These targets are critical elements of embryonic stem cell self-renewal programs, and their 
repression is required for differentiation. Thus, it appears that reduced LIN28 and increased let7 
expression promotes a transition from pluripotency to tissue-specific programming [38]. Conversely, 
regulation of LIN28 and let7g by Oct4/Sox2/Nanog/Tcf3 in ES cells [37] promotes self-renewal and 
pluripotency. In sum, the interplay between LIN28 and let7 carefully regulates the balance between 
stemness and differentiation [39]. 
The miR17-92 cluster appears to be critical in both development and tumorigenesis in 
hematopoietic and solid organs. This polycistronic gene cluster, located on a region of ch. 13q13 that 
frequently undergoes copy number changes in human cancers, contains six highly conserved miRNAs 
that interact with apoptotic and cell cycle pathways [40]. In addition, the miR17-92 cluster is highly 
represented in expression profiles from embryonic stem cell populations, in which it appears to 
promote pluripotency and self-renewal [32]. C-MYC, one of the critical pluripotency genes in stem 
cells, as well as an established oncogene, promotes the expression of the miR17-92 cluster, which in 
turn downregulates E2F1 expression, whose accumulation drives the G1 to S phase transition in the 
cell cycle [41]. The E2F factors also bind the miR17-92 promoter, suggesting the presence of an 
autoregulatory loop [42]. Thus, the miR17-92 cluster appears to regulate the effects of c-myc on 
cellular proliferation via its interaction with the E2F factors; as such, and possibly as a function of the 
cell type and environment, the miR17-92 cluster can either suppress or permit the pro-proliferative 
effects of c-myc. Evidence that this cluster has oncogenic or tumor suppressor properties is supported 
by cytogenetic studies demonstrating frequent amplification [40] or loss of heterozygosity [43,44] at 
the 13q31 locus in different tumor types. 
The miR302 family targets numerous genes important in early human embryogenesis [45,46], and 
is co-expressed with other ES cell genes such as Oct3/4, Sox2 and Nanog. Transfection of miR302 into 
cancer cell lines suppresses the expression of genes important in development and differentiation and 
appears to re-program differentiated cancer cells into a pluripotent ES-like state [45]. These miR302 
reprogrammed cancer cells are relatively quiescent, as compared to other iPS cells. Via inhibition of 
cyclin D1/D2, CDK2, and BMI-1 expression, miR302 blocks G1-S cell cycle transition, leading to a 
low proliferation rate [47]. miR302 expression is induced by Oct4; together, Oct4 and miR302 silence 
the transcription factor NR2F2. Decreased levels of Oct4 and miR302 permit NR2F2 expression. In a 
positive feedback loop, NR2F2 represses Oct4 and regulates neural specification genes in early 
differentiation states [48]. Interestingly, in glioma-initiating cells, expression of the miR302-367 cluster of Cancers 2011, 3                                       
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miRNAs occurs in tandem with suppression of Oct4 and Nanog and triggers a loss of self-renewal [49], 
findings which suggest disparate mechanisms of action in different cellular contexts. 
3. Role of miRNA in Cancer Stem Cells 
Cancer stem cells are broadly defined as a population that exhibits stem-cell specific cell surface or 
intracellular markers, forms spherules, and forms tumors when implanted into a receptive animal 
model. There is growing understanding of the regulatory networks that drive acquisition of the cancer 
stem cell phenotype and the role of miRNAs in these networks. Several organ-specific examples follow. 
3.1. miR200 Family and Breast Carcinoma 
Epigenetic regulation is key both in embryonic stem cells and in cancer. In ES cells, stemness is 
maintained by polycomb group (PcG) protein-mediated organization of promoter chromatin. Acting on 
CpG islands within the promoters of lineage commitment genes, PcG proteins facilitate normal 
development via histone modifications that allow a balanced but dynamic gene regulatory state [50]. 
Recent evidence suggests that similar regulatory elements act in tumorigenesis, with PcG family 
members recruiting DNA methyltransferases to CpG islands and leading to stable silencing of tumor 
suppressor genes via DNA hypermethylation [51]. These methylation states modulate, and are 
modulated by, miRNAs. miRNAs located within CpG islands can be epigenetically silenced, an 
important event in tumorigenesis when the miRNA targets an oncogene (as is the case for the   
miR127-BCL6 pair) [52]. Expression of the miR29 family of miRNAs binds and silences two DNA 
methyltransferases that are commonly upregulated in lung cancer, leading to restored expression of 
epigenetically-silenced tumor suppressor genes [53]. 
In a model of Src oncogene-transformed breast epithelial cells, CSC formation is dependent upon 
downregulation of miR200 family members [24]. In this model, the CSC population is defined as a 
CD44-positive, mammosphere-forming subset of cells that can form tumors in immune-deficient mice. 
The authors of this study note that while downregulation of miRNAs such as let7 occurs in both 
neoplastic transformation and CSC formation, expression of the miR200 family members is 
specifically altered in CSCs, suggesting a central role for miR200 in formation of this population. The 
mechanism of action of miR200 in regulating CSC formation appears to be epigenetic. Namely, 
miR200 interacts with Suz12, a component of the PRC2 polycomb complex. During neoplastic 
transformation, PRC2 methylates histones leading to aberrant silencing of tumor suppressor genes. 
miR200 expression inhibits Suz12 action; silencing of miR200 leads to significantly increased Suz12 
transcript and protein expression in the CSC population. Suz12 consequently binds multiple targets in 
the genome, leading to histone methylation and gene silencing of multiple targets including WNT1, 
Sox2, and CDH1 (E-cadherin). The effects of Suz12 on e-cadherin in particular may contribute to the 
invasive and metastatic potential of breast carcinoma, with high miR200, low Suz12 and high   
e-cadherin levels associated with primary tumors and low miR200, high Suz12, and low e-cadherin 
observed in metastatic tumors [24]. Overexpression of miR200 leads to CSC death, raising the 
possibility that miRNAs may be useful therapeutics, especially in combination with chemotherapeutic 
drugs better suited to kill the non-CSC tumor population. Cancers 2011, 3                                       
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3.2. MicroRNAs, Microvesicles, and Metastases 
MicroRNAs are thought to contribute to priming a stromal niche for tumor cells; in the context of 
metastases, miRNA delivery via microparticles permits “horizontal communication” between tumor 
and recipient stroma, even before the tumor implants at that site [54]. Microvesicles are   
plasma-membrane-derived particles that may contain cell-type specific proteins, nucleic acids, and 
other bioactive substances; these are released into the extracellular environment, exerting local and, if 
captured by the blood stream, distant effects. As compared to normal tissues, tumors shed 
microvesicles into the circulation in large amounts. The microvesicle fraction in the serum is enriched 
for miRNAs, and several studies indicate that these miRNAs have angiogenic potential [55-57]. One 
study demonstrated a CD105-expressing cancer stem cell population that preferentially produces 
microvesicles rich in pro-angiogenic mRNAs and miRNAs that enhance tumor implantation in a 
mouse model of renal cell carcinoma metastases to the lung [57]. The profile of the RNAs within the 
microvesicles from the cancer stem cell fraction appears to be enriched in pro-angiogenic and   
pro-tumorigenic factors that may enable the cancer stem cells to coordinate the spread of tumor. The 
mRNAs and miRNAs are delivered by the microvesicles to recipient cells, where they can be 
translated into proteins [58,59] or potentially trigger epigenetic reprogramming. 
3.3. Lin28B in Colon Adenocarcinoma 
LIN28 and its homologue LIN28B are key regulators of stem cell pluripotency, as discussed above. 
It is demonstrably important in colonic development, and overexpression of LIN28B is associated with 
tumorigenesis in multiple organs. LIN28 and LIN28B overexpression is found in approximately 15% 
of human cancers and is associated with poor outcomes [60]. Recently, King et al. demonstrated that 
LIN28B overexpression in colon adenocarcinoma in particular is a poor prognostic indicator [61]. 
Activated protein C (APC) mutations are common in colon adenocarcinoma, leading to Wnt pathway 
upregulation. Targets of the Wnt pathway include c-myc, which in turn upregulates LIN28B 
expression [62]. Constitutive expression of LIN28B in colon cancer cell lines turns on colonic stem 
cell markers PROM1 and LGR5 and enhances the metastatic capacity of these cancer cells in a mouse 
model [61] The effects of LIN28B in this model appears to be driven in part by the enhanced 
invasiveness and motility of LIN28B-overexpressing tumor cells. In contrast to embryonic stem cells, 
where let7 and LIN28 co-regulate each others’ expression, let7 fails to inhibit the effects of LIN28B, 
suggesting that LIN28B can act independently of Let7 in this colon cancer model [63]. 
Various markers have been proposed to define the stem cell component of colon adenocarcinoma, 
including CD44, CD133, and CD166 [64-66]. Of note, one study of miRNA expression in CD133+ 
HT29 colon cancer cells failed to identify significant differences in let7 or LIN28B expression in this 
population as compared to a CD133-population, despite other features of stemness that were unique to 
the CD133+ cells [67]. These findings suggest that miRNA expression profiles may vary depending on 
the type of tissue examined (i.e., primary tumor vs. cell line), as well as for individual tumor subtypes. 
Further studies are needed to establish a link between the colon cancer stem cell population and 
dysregulated LIN28 activity.  Cancers 2011, 3                                       
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3.4. Tobacco Carcinogens and Epigenetic Regulation of miRNAs in Lung Carcinoma 
The carcinogens in tobacco smoke are recognized to induce epigenetic changes in the DNA of 
epithelial cells of the upper aerodigestive tract [68]. These carcinogens, including methylnitrosylurea 
and benzo(a)pyrenediol epoxide, damage DNA, triggering the recruitment of DNA methyltransferase 
and histone modification [69]. Enrichment of histone marks (reversible methylation) and DNA 
cytosine methylation leads to gene silencing and is thought to induce dedifferentiation and acquisition 
of stem cell characteristics [51]. Exposure of lung epithelial cell cultures to tobacco carcinogens leads 
to epigenetic silencing of miR200b, miR200c and miR205 and phenotypic epithelial to mesenchymal 
transition (EMT) [69]. Acquisition of stem cell markers (CD44, CD133, ALDH1) and spheroid 
formation occurs after prolonged exposure to carcinogens, however this model does not induce 
complete transformation. Re-expression of miR200 family members or miR205 only partially reverses 
the stem cell phenotype, an observation that highlights the complex deregulation that occurs   
in carcinogenesis. 
3.5. miR34 in p53-Mutated Pancreatic Cancer Stem Cells 
P53, a key cell cycle regulator and tumor suppressor gene, is commonly mutated and inactivated in 
aggressive malignancies such as pancreatic adenocarcinoma. Studies examining the effects of tumor 
suppressor genes on miRNAs have demonstrated that p53 activates the transcription of the miR34 
family of miRNAs. In turn, miR34 also acts as a tumor suppressor gene, via inhibition of bcl2, 
notch1/2 and c-met, all central pro-survival and pro-proliferative molecules [70,71]. CD44+/CD133+ 
cancer stem cell populations in p53-mutated pancreatic cancer cell lines contain low levels of miR34 
and high levels of bcl2 and notch1/2. Re-expression of miR34 in this population triggers a loss of the 
CSC population, as demonstrated by a marked reduction in the CD44+/CD133+ subset, as well as 
inhibition of spherule formation and in vivo tumor growth. Importantly, overexpression of miR34 in 
these cells restored their chemo- and radiotherapy sensitivity. These observations suggest that miR34 
is an important negative regulator of cancer stem cell renewal and may hold promise as a form of 
molecular therapy in pancreatic cancer [72]. 
3.6. miRNAs in Glioblastoma and Medulloblastoma 
The presence of a cancer stem cell or tumor “initiating” population is well accepted in the highly 
malignant brain tumor glioblastoma multiforme (GBM), and is defined as CD133+ cells with neural 
stem cell-like properties (i.e., capable of forming neurospheres in vitro and neural tumors in in vivo 
models) [73]. Selected miRNAs are differentially expressed in CD133+ and CD133-GBM cells; 
miR9/9* are highly expressed in the stem cell fraction, where they appear to act as oncogenes by 
inhibiting CAMTA1, a tumor suppressor gene that appears to regulate cell proliferation [74]. 
Medulloblastomas are thought to originate from a number of different cerebellar cell populations, 
including granular cell progenitors and possibly neuronal stem cells. Sonic hedgehog (Shh) pathway 
drives cerebellar cell proliferation in normal development; abnormal activation of the Shh pathway in 
neural stem cells (NSC) triggers the development of medulloblastoma in animal models [75]. Notch 
proteins are also thought to play an important role in medulloblastoma pathogenesis. There is Cancers 2011, 3                                       
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conflicting evidence as to the interaction of Notch and Shh [76], however both pathways appear to 
converge on helix-loop-helix factor HES-1, a transcription factor that is critical to progenitor cell  
self-renewal. miR199-5b blocks HES-1 translation, driving neuronal differentiation. In medulloblastoma 
this effect is specific to the CD133+ population [77]. Other miRNAs that interact with these pathways 
include miR17-92 and miR34a. miR17-92 promotes medulloblastoma formation in cerebellar granular 
cell precursors with constitutive Shh activation [78]. miR34a expression is induced by p53, inhibiting 
growth and triggering apoptosis, and it acts as a tumor suppressor in medulloblastoma via its negative 
regulation of the Notch ligand Delta-like 1 (Dll1) [79]. de Antonellis and colleagues demonstrate that 
miR34a plays a central role in Dll1-Notch signaling, regulating Notch 1 and 2 differentially depending 
on cellular context to drive differentiation and trigger apoptosis. Using an adenoviral-delivery system, 
these authors demonstrate that miR34 can drive neural differentiation of tumor neurospheres and 
impair tumor growth in a mouse model of medulloblastoma. 
4. miRNAs as Therapeutic Predictors and as Therapy 
There is ample evidence to suggest that miRNA expression profiles can predict response or 
resistance to an array of chemotherapeutics. For instance, downregulation of miR200b, -194 and -212 
and upregulation of miR192, -424 and -98 are associated with docetaxel resistance in non small cell 
lung carcinoma [80]. Patients with advanced ovarian cancer whose tumors had reduced levels of tumor 
let7i expression had a shorter progression free survival [81]. In vitro, let7i-low ovarian and breast 
cancer cells demonstrate cisplatin resistance, suggesting that let7i modulates the effects of 
chemotherapy and may serve as predictive biomarker in ovarian carcinoma [81].  
Attempts at miRNA inhibition and replacement have yielded some promising results. 
Oligonucleotides engineered to block endogenous miRNAs (so-called antagomiRs) can be delivered 
intravenously to specifically reduce the expression of their target miRNA and alter downstream 
mRNAs [82]. Thus, it is technically feasible to silence oncogenic miRNAs, suggesting that this 
approach might serve as a novel cancer therapy. Conversely, Kota et al. administered miR26a in a 
mouse hepatocellular carcinoma model using an adenoviral vector. These authors argue that 
“replacement” of miRNAs that are lost in a tumor-specific manner but are otherwise highly expressed 
in normal tissues should be associated with decreased toxicity. In fact, their model demonstrated that 
systemic miR26a therapy blocked hepatocellular carcinoma cell cycle progression and induced tumor 
cell apoptosis with a minimum of side effects [83]. In a conceptually similar model, Trang et al. 
demonstrated the efficacy of let7 replacement in reducing tumor burden using an intranasal, 
adenovirus delivery system in mice with KRAS-mutated lung adenocarcinoma [84]. 
In general, the global effects of miRNAs on the expression of mRNAs involved in cell cycle, 
survival, oncogenic pathways, and differentiation suggests that miRNA therapeutics may exert 
powerful effects on tumor cells, in particular in targeting the cancer stem cell niche. Bao et al. 
examined the efficacy of a novel synthetic curcumin analogue in treating pancreatic carcinoma. This 
curcumin analogue suppresses miR21 leading to re-expression of the tumor suppressor PTEN, and is 
associated with tumor cell death; the authors demonstrated that this agent effectively killed the cancer 
stem cell population, suggesting this may be a promising approach to treating patients with 
gemcitabine-resistant pancreatic cancer [85]. Cancers 2011, 3                                       
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Dissecting the miRNA/mRNA pathways responsible for enabling local and distant tumor 
progression may uncover novel therapeutic targets. The miR200 family of miRNAs appears to play a 
central role in tumor invasion and metastasis via their negative regulation of ZEB1 and ZEB2, zinc 
finger proteins that act as transcriptional repressors of e-cadherin [86,87]. miR200 family members 
regulate the epithelial-mesenchymal transition (EMT), via mediation of growth factor signaling 
pathways including transforming growth factor-beta and platelet-derived growth factor D [88]. 
Overexpression of one miR200 family member, miR429, has been shown to reverse EMT in 
ovarian cancer cell lines [89]. Given the feasibility of miRNA adenoviral delivery, these observations 
raise the possibility that miR200 “replacement”, could serve as a novel metastasis-directed therapy. 
5. Conclusions 
The discovery of miRNAs has led to significant advances in our understanding of the normal and 
pathologic cellular regulatory systems. Much remains to be learned about cancer stem cells and their 
genetic and epigenetic regulation. However, given that many miRNA species serve as master 
regulators both in organism development and disease, they offer promising new targets in diagnosing 
and treating cancer, particularly in targeting the cancer stem cell population. 
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